AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (currently amended) A compound of the formula



(I)

wherein R^1 is $(C_1\text{-}C_6)$alkyl, optionally substituted by $(C_3\text{-}C_{10})$cycloalkyl, or $(C_6\text{-}C_{10})$aryl, ~~$(C_1\text{-}C_{10})$heterocyclyl, or $(C_1\text{-}C_{10})$heteroaryl,~~ wherein each of said $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, or $(C_6\text{-}C_{10})$aryl~~, $(C_1\text{-}C_{10})$heterocyclyl, or $(C_1\text{-}C_{10})$heteroaryl~~ are optionally substituted by one to three ~~suitable~~ moieties independently selected from the group consisting of hydroxy, halogen, ~~CN~~ -CN, $(C_1\text{-}C_6)$alkyl, $HO(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl-$NH(C{=}O)$-, $NH_2(C{=}O)$-, $(C_1\text{-}C_6)$alkoxy, ~~or~~ and $(C_3\text{-}C_{10})$cycloalkyl, wherein said $(C_3\text{-}C_{10})$cycloalkyl is optionally substituted by one or more moieties selected from halogen, or $(C_1\text{-}C_6)$alkyl-;

R^2 is hydrogen, halogen, -CN, ~~and~~ or $(C_1\text{-}C_6)$alkyl, wherein said $(C_1\text{-}C_6)$alkyl is optionally substituted by one to three ~~suitable~~ moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $-CF_3$, CF_3O-, $(C_1\text{-}C_6)$alkyl-NH-, $[(C_1\text{-}C_6)\text{alkyl}]_2$-N-, $(C_1\text{-}C_6)$alkyl-S-, $(C_1\text{-}C_6)$alkyl-$(S{=}O)$-, $(C_1\text{-}C_6)$alkyl-(SO_2)-, $(C_1\text{-}C_6)$alkyl-O-$(C{=}O)$-, formyl, $(C_1\text{-}C_6)$alkyl-$(C{=}O)$-, and $(C_3\text{-}C_6)$cycloalkyl; and

R^3 is a ~~suitably~~ substituted nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of the formula:



II or III

or the pharmaceutically acceptable salts or solvates or prodrugs thereof.

2. (currently amended) A compound of the formula



(I)

wherein R^1 is (C_1-C_6)alkyl, optionally substituted by (C_3-C_{10})cycloalkyl, or (C_6-C_{10})aryl, ~~(C_1-C_{10})heterocyclyl, or (C_1-C_{10})heteroaryl,~~ wherein each of said (C_1-C_6)alkyl, (C_3-C_{10})cycloalkyl, or (C_6-C_{10})aryl~~, (C_1-C_{10})heterocyclyl, or (C_1-C_{10})heteroaryl~~ are optionally substituted by one to three ~~suitable~~ moieties independently selected from the group consisting of hydroxy, halogen, ~~CN~~ -CN, (C_1-C_6)alkyl, HO(C_1-C_6)alkyl, (C_1-C_6)alkyl-NH(C=O)-, NH_2(C=O)-, (C_1-C_6)alkoxy, ~~or~~ and (C_3-C_{10})cycloalkyl, wherein said (C_3-C_{10})cycloalkyl is optionally substituted by one or more moieties selected from halogen, or (C_1-C_6)alkyl-;

R^2 is hydrogen, halogen, -CN, and (C_1-C_6)alkyl, wherein said (C_1-C_6)alkyl is optionally substituted by one to three ~~suitable~~ moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, -CF_3, CF_3O-, (C_1-C_6)alkyl-NH-, [(C_1-C_6)alkyl]$_2$-N-, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-(S=O)-, (C_1-C_6)alkyl-(SO_2)-, (C_1-C_6)alkyl-O-(C=O)-, formyl, (C_1-C_6)alkyl-(C=O)-, and (C_3-C_6)cycloalkyl;

R^3 is a nitrogen linked (C_1-C_{10})heterocyclyl of the formula:



IV V

wherein R^4 and R^5 are independently selected from the group of ~~suitable~~ substituents~~, such as~~ consisting of hydrogen, halo, hydroxy, -CN, HO-$(C_1$-$C_6)$alkyl, and $(C_1$-$C_6)$alkyl, wherein said $(C_1$-$C_6)$alkyl is optionally substituted with one to three fluoro, $(C_1$-$C_6)$alkoxy optionally substituted with one to three fluoro, HO_2C-, $(C_1$-$C_6)$alkyl-O-(C=O)-, $R^6R^8N(O_2S)$-, $(C_1$-$C_6)$alkyl-(O_2S)-NH-, $(C_1$-$C_6)$alkyl-O_2S-$[(C_1$-$C_6)$alkyl-N]-, $R^6R^8N(C=O)$-, $R^6R^8N(CH_2)_m$-, $(C_6$-$C_{10})$aryl, $(C_3$-$C_8)$cycloalkyl, ~~$(C_1$-$C_{10})$heteroaryl, $(C_1$-$C_{10})$heterocyclyl,~~ $(C_6$-$C_{10})$aryl-O-, or $(C_3$-$C_8)$cycloalkyl-O-, ~~$(C_1$-$C_{10})$heteroaryl-O- and $(C_1$-$C_{10})$heterocyclyl-O-~~; and

R^7 is independently selected from the group of ~~suitable~~ substituents ~~such as~~ consisting of hydrogen and $(C_1$-$C_6)$alkyl optionally substituted with one to three halogens, hydroxy, -CN, $(C_1$-$C_6)$alkoxy-, $(C_2$-$C_6)$alkenoxy, $(C_1$-$C_6)$alkyl-SO_2-, NH_2-, $((C_1$-$C_6)$alkyl$)_n$-N-, $((C_2$-$C_6)$alkenyl$)_n$-N-, $((C_2$-$C_6)$alkynyl$)_n$-N-, $NH_2(C=O)$-, $(C_1$-$C_6)$alkyl-(C=O)N-, $((C_1$-$C_6)$alkyl$)_n$-N-(C=O)-, $(C_2$-$C_6)$alkenyl-(C=O)N-, $((C_2$-$C_6)$alkenyl$)_n$-N-(C=O)-, $(C_2$-$C_6)$alkynyl-(C=O)N-, $((C_2$-$C_6)$alkynyl$)_n$-N-(C=O)-, $(C_1$-$C_6)$alkyl-(C=O)-, $(C_2$-$C_6)$alkenyl-(C=O)-, $(C_2$-$C_6)$alkynyl-(C=O)-, $(C_3$-$C_{10})$cycloalkyl-(C=O)-, ~~$((C_1$-$C_{10})$heterocyclyl-(C=O)-~~, $(C_6$-$C_{10})$aryl-(C=O), ~~$(C_1$-$C_{10})$heteroaryl-(C=O)~~, $(C_1$-$C_6)$alkyl-(C=O)O-, $(C_2$-$C_6)$alkenyl-(C=O)O-, $(C_2$-$C_6)$alkynyl-(C=O)O-, $(C_1$-$C_6)$alkyl-O(C=O)-, $(C_2$-$C_6)$alkenyl-O-(C=O)-, $(C_2$-$C_6)$alkynyl-O-(C=O)-, and $(C_3$-$C_{10})$cycloalkyl~~, $(C_6$-$C_{10})$aryl, $(C_1$-$C_{10})$heterocyclyl, and $(C_1$-$C_{10})$heteroaryl~~;

wherein R^4, R^5 and R^7 may each be optionally substituted on any aliphatic or aromatic carbon atom by one to three ~~suitable~~ moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, $(C_1$-$C_6)$alkyl, $(C_1$-

C_6)alkoxy, -CF_3, CF_3O-, (C_1-C_6)alkyl-NH-, [(C_1-C_6)alkyl]$_2$-N-, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-(S=O)-, (C_1-C_6)alkyl-(SO_2)-, (C_1-C_6)alkyl-O-(C=O)-, formyl, (C_1-C_6)alkyl-(C=O)-, and (C_3-C_6)cycloalkyl;

R^6 and R^8 are each independently selected from the group consisting of hydrogen, (C_1-C_6)alkyl, HO-(C_2-C_6)alkyl and (C_3-C_8)cycloalkyl~~, or R^6 and R^8 may optionally be taken together with the nitrogen atom to which they are attached to form a 3 to 8 membered heterocycle~~;

n is an integer from zero to two; and

m is an integer from one to two;

or the pharmaceutically acceptable salts or solvates or prodrugs thereof.

3. (original) A compound of any of the preceding claims wherein R^2 is chloro, methyl or ethyl.

4. (original) A compound of any of the preceding claims wherein R^3 is a nitrogen linked (C_1-C_{10})heterocyclyl of formula (IV):



(IV)

R^4 is hydrogen or methyl,

and R^7 is selected from the group consisting of:



5. (currently amended) A compound of any of ~~the preceding~~ claims 1, 2, or 3 wherein R^3 is a nitrogen linked (C_1-C_{10})heterocyclyl of formula (IV), R^4 is hydrogen or methyl, and R^7 is



6. (currently amended) A compound of any of ~~the preceding~~ claims 1, 2, or 3 wherein R^3 is a nitrogen linked (C_1-C_{10})heterocyclyl of formula (IV), R^4 is hydrogen or methyl, and R^7 is selected from the group consisting of:



7. (currently amended) A compound of any of ~~the preceding~~ claims 1, 2, or 3 wherein R^3 is a nitrogen linked (C_1-C_{10})heterocyclyl of formula (IV), R^4 is hydrogen or methyl, and R^7 is



8. (currently amended) A compound of any of ~~the preceding~~ claims 1, 2, or 3 wherein R^3 is a nitrogen linked (C_1-C_{10})heterocyclyl of formula (IV), R^4 is hydrogen or methyl, and R^7 is selected from:



9. (currently amended) A compound of any of ~~the preceding~~ claims 1, 2, or 3 wherein R^3 is a nitrogen linked (C_1-C_{10})heterocyclyl of formula (IV), R^4 is hydrogen or methyl, and R^7 is selected from:



10. (currently amended) A compound selected from the group consisting of:

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-methoxy-ethyl)-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-(5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-(3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-ethyl)-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

2-Chloro-5-(4-cyanomethyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-methoxy-ethyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

2-Chloro-5-(4-cyanomethyl-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-N-(1-hydroxy-cycloheptyl methyl)-benzamide;

2-Chloro-N-(1-hydroxy-3,3-dimethyl-cyclohexylmethyl)-5-(3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-benzamide;

5-(4-Carbamoylmethyl-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-2-chloro-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-ethyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

5-[4-(2-Amino-ethyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-2-chloro-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide; and

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-2-methyl-propyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide[[.]] , or the pharmaceutically acceptable salts or solvates or prodrugs thereof.

11. (currently amended) A pharmaceutical composition for treating a IL-1 mediated disease in a mammal in need thereof, comprising a therapeutically effective amount of a compound according to claim 1 or 2 or a salt or prodrug thereof, and a pharmaceutically acceptable carrier or diluent.

12. (withdrawn) A method of treating a IL-1 mediated disease in a mammal in need thereof, comprising administering to said mammal a therapeutically effective amount of a compound according to claim 1 or a salt or prodrug thereof.